Patents Assigned to AbGenomics Cooperatief U.A.
  • Methods of treating with anti-PSGL-1 antibodies
    Patent number: 10030075
    Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: July 24, 2018
    Assignee: AbGenomics Cooperatief U.A.
    Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
  • Methods of treating GVHD and transplant rejection with anti-PSGL-1 antibodies
    Patent number: 9631019
    Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: April 25, 2017
    Assignee: AbGenomics Cooperatief U.A.
    Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
  • T-cell death-inducing epitopes
    Patent number: 9494574
    Abstract: Cell death-inducing epitopes and polypeptides containing same. Also disclosed are compounds for inducing death of activated T-cells, a method of producing antibodies to the epitopes, a method of identifying compounds that bind to the epitopes, a method of inducing death of activated T-cells, and pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: July 28, 2010
    Date of Patent: November 15, 2016
    Assignee: AbGenomics Cooperatief U.A.
    Inventors: Rong-Hwa Lin, Chung Nan Chang
  • Anti-PSGL-1 antibodies and methods of inducing cell death of an activated T cell
    Patent number: 8828397
    Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: September 9, 2014
    Assignee: AbGenomics Cooperatief U.A.
    Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
  • T-CELL DEATH-INDUCING EPITOPES
    Publication number: 20140065176
    Abstract: Cell death-inducing epitopes and polypeptides containing same. Also disclosed are compounds for inducing death of activated T-cells, a method of producing antibodies to the epitopes, a method of identifying compounds that bind to the epitopes, a method of inducing death of activated T-cells, and pharmaceutical compositions containing the compounds.
    Type: Application
    Filed: August 29, 2013
    Publication date: March 6, 2014
    Applicant: AbGenomics Cooperatief U.A.
    Inventors: Rong-Hwa Lin, Chung Nan Chang
  • Anti-PSGL-1 antibodies
    Patent number: 8663641
    Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: March 4, 2014
    Assignee: AbGenomics Cooperatief U.A.
    Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
  • Methods of reducing T cell-mediated immune responses with multimeric P-selectin and/or E-selectin compounds
    Patent number: 8628775
    Abstract: Multimeric compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The multimeric compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as inflammatory diseases, autoimmune diseases, transplant rejection, and allergic diseases.
    Type: Grant
    Filed: September 18, 2009
    Date of Patent: January 14, 2014
    Assignee: AbGenomics Cooperatief U.A.
    Inventors: Rong-Hwa Lin, Chung Nan Chang
  • Screening for modulators of PSGL-1 with respect to T cell or NK cell death
    Patent number: 8557579
    Abstract: Compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as autoimmune diseases, transplant rejection, and allergic diseases.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: October 15, 2013
    Assignee: AbGenomics Cooperatief U.A.
    Inventors: Rong-Hwa Lin, Chung-Hsiun Wu, Pei-Ling Hsu
  • ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
    Publication number: 20130251708
    Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.
    Type: Application
    Filed: April 17, 2013
    Publication date: September 26, 2013
    Applicant: ABGENOMICS COOPERATIEF U.A.
    Inventors: STEFAN BASSARAB, BARBARA ENENKEL, PATRICK GARIDEL, HEIDRUN SCHOTT, SANJAYA SINGH, TOBIAS LITZENBURGER
  • ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
    Publication number: 20130209449
    Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.
    Type: Application
    Filed: June 12, 2012
    Publication date: August 15, 2013
    Applicant: AbGenomics Cooperatief U.A.
    Inventors: Stefan Bassarab, Barbara Enenkel, Patrick Garidel, Heidrun Schott, Sanjaya Singh, Tobias Litzenburger
  • ANTI-PSGL-1 ANTIBODIES
    Publication number: 20130101587
    Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.
    Type: Application
    Filed: September 14, 2012
    Publication date: April 25, 2013
    Applicant: AbGenomics Cooperatief U.A.
    Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
  • Anti-PSGL-1 antibodies
    Patent number: 8361472
    Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: January 29, 2013
    Assignee: AbGenomics Cooperatief U.A.
    Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
  • MODULATORS OF P-SELECTIN GLYCOPROTEIN LIGAND 1
    Publication number: 20130011861
    Abstract: Compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as autoimmune diseases, transplant rejection, and allergic diseases.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Applicant: AbGenomics Cooperatief U.A..
    Inventors: Rong-Hwa Lin, Chung-Hsiun Wu, Pei-Ling Hsu
  • ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
    Publication number: 20130011391
    Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.
    Type: Application
    Filed: June 12, 2012
    Publication date: January 10, 2013
    Applicant: AbGenomics Cooperatief U.A.
    Inventors: Stefan Bassarab, Barbara Enenkel, Patrick Garidel, Heidrun Schott, Sanjaya Singh, Tobias Litzenburger
  • Methods of modulating T cell-mediated immune responses with anti-P-selectin glycoprotein ligand 1 antibodies
    Patent number: 8298540
    Abstract: Compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as autoimmune diseases, transplant rejection, and allergic diseases.
    Type: Grant
    Filed: June 29, 2009
    Date of Patent: October 30, 2012
    Assignee: AbGenomics Cooperatief U.A.
    Inventors: Rong-Hwa Lin, Chung-Hsiun Wu, Pei-Ling Hsu
  • Methods of inducing cell death of an activated T cell with anti-PSGL-1 antibodies
    Patent number: 8287871
    Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: October 16, 2012
    Assignee: AbGenomics Cooperatief U.A.
    Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
  • T-CELL DEATH-INDUCING EPITOPES
    Publication number: 20110178270
    Abstract: Cell death-inducing epitopes and polypeptides containing same. Also disclosed are compounds for inducing death of activated T-cells, a method of producing antibodies to the epitopes, a method of identifying compounds that bind to the epitopes, a method of inducing death of activated T-cells, and pharmaceutical compositions containing the compounds.
    Type: Application
    Filed: July 28, 2010
    Publication date: July 21, 2011
    Applicant: AbGenomics Cooperatief U.A.
    Inventors: Rong-Hwa Lin, Chung Nan Chang
  • ANTI-PSGL-1 ANTIBODIES
    Publication number: 20110172397
    Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.
    Type: Application
    Filed: August 17, 2010
    Publication date: July 14, 2011
    Applicant: AbGenomics Cooperatief U.A.
    Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
  • Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
    Patent number: 7744888
    Abstract: Compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as autoimmune diseases, transplant rejection, and allergic diseases.
    Type: Grant
    Filed: January 18, 2002
    Date of Patent: June 29, 2010
    Assignee: AbGenomics Cooperatief U.A.
    Inventors: Rong-Hwa Lin, Chung-Hsiun Wu, Pei-Ling Hsu
  • MODULATORS OF P-SELECTIN GLYCOPROTEIN LIGAND 1
    Publication number: 20090304709
    Abstract: Compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as autoimmune diseases, transplant rejection, and allergic diseases.
    Type: Application
    Filed: June 29, 2009
    Publication date: December 10, 2009
    Applicant: AbGenomics Coöperatief U.A.
    Inventors: RONG-HWA LIN, CHUNG-HSIUN WU, PEI-LING HSU